Agios Pharmaceuticals
Tracked across 3 events · 18 articles · First seen Apr 23, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Agios is the central company seeking FDA approval for mitapivat in sickle cell disease; the priority review is a major catalyst, with shares rising over 12%.
Jul 07, 2026 · 6 articles
Regulatory
Impact: Agios is the subject of the investigation and the company that discontinued tebapivat development, causing a stock price drop. The investigation could result in legal and financial repercussions.
Jul 28, 2026 · 6 articles
Business
Impact: Orlando Oliveira previously held senior leadership roles at Agios Pharmaceuticals.
Apr 23, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Agios Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard